Antengene Corporation Ltd banner

Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 5.36 HKD 14.04% Market Closed
Market Cap: HK$3.6B

Multiples-Based Value

The Multiples-Based Value of one Antengene Corporation Ltd stock under the Base Case scenario is 0.73 HKD. Compared to the current market price of 5.36 HKD, Antengene Corporation Ltd is Overvalued by 86%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
Base Case
0.73 HKD
Overvaluation 86%
Multiples-Based Value
Price HK$5.36
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Antengene Corporation Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Antengene Corporation Ltd
HKEX:6996
3.6B HKD 30.5 -13.4 -12.5 -11.3
US
Eli Lilly and Co
NYSE:LLY
901.8B USD 13.8 43.7 29.5 31.4
US
Johnson & Johnson
NYSE:JNJ
587.8B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.7 11.6 13.1
UK
AstraZeneca PLC
LSE:AZN
233B GBP 5.3 30.6 16.9 23.8
US
Merck & Co Inc
NYSE:MRK
299B USD 4.6 16.4 10.1 12.3
CH
Novartis AG
SIX:NOVN
235.8B CHF 5.4 21.6 13.4 17.2
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 9
US
Pfizer Inc
NYSE:PFE
162.3B USD 2.6 20.9 7.9 10.6
US
Bristol-Myers Squibb Co
NYSE:BMY
124.3B USD 2.6 17.6 7.4 9.1
P/E Multiple
Earnings Growth PEG
CN
Antengene Corporation Ltd
HKEX:6996
Average P/E: 22.5
Negative Multiple: -13.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.7
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.7
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30.6
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
CH
Novartis AG
SIX:NOVN
21.6
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
20.9
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.6
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Antengene Corporation Ltd
HKEX:6996
Average EV/EBITDA: 49.5
Negative Multiple: -12.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.5
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.9
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.4
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.9
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Antengene Corporation Ltd
HKEX:6996
Average EV/EBIT: 108.6
Negative Multiple: -11.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
13.1
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.8
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2.1
CH
Novartis AG
SIX:NOVN
17.2
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.6
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.1
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett